Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SCN1A | P35498 | 3/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3801806 | 0.85 | SIGMAR1 (0.41) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| SCHEMBL19471222 | 0.85 | SIGMAR1 (0.42) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| SCHEMBL4905532 | 0.84 | SIGMAR1 (0.49) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| SCHEMBL5184742 | 0.84 | SIGMAR1 (0.49) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| SCHEMBL5183470 | 0.84 | SIGMAR1 (0.49) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| Cizolirtine SCHEMBL2776433 | 0.83 | SLC6A2 (0.65) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| Cizolirtine SCHEMBL290138 | 0.83 | SLC6A2 (0.65) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| SCHEMBL17847999 | 0.83 | LMNA (0.47) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| Hydrochloric Acid SCHEMBL5186556 | 0.83 | HTT (0.49) | SIGMAR1HTTSCN1ASCN2ASCN3A | |
| Hydrochloric Acid SCHEMBL5186565 | 0.83 | HTT (0.49) | SIGMAR1HTTSCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| EP-1786419-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS (IN PARTICULAR CIZOLIRTIN CITRATE) FOR THE TREATMENT OF OPIOID ADDICTION | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1786420-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1784178-A1 | ARYL (OR HETEROARYL) AZOLYLCARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-16 | — | — | EP | claimed |
| US-20060194860-A1 | Pharmaceutical compositions containing aryl or heteroaryl azolylcarbinol compounds | GRUENENTHAL GMBH (DE) | 2006-08-31 | — | — | US | claimed |
| EP-1695704-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | claimed |
| WO-2006087147-A2 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF FIBROMYALGIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-24 | — | — | WO | claimed |
| EP-1690537-A1 | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-16 | — | — | EP | claimed |
| EP-1648450-A1 | MEDICAMENTS CONTAINING DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS | Grünenthal GmbH (DE) | 2006-04-26 | — | — | EP | claimed |
| EP-1642577-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain | Laboratorios del Dr. Esteve S.A. (ES) | 2006-04-05 | — | — | EP | claimed |
| WO-2006027226-A1 | DERIVATIVES OF ARYL(OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2006-03-16 | — | — | WO | claimed |
| WO-2006027221-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS (IN PARTICULAR CIZOLIRTIN CITRATE) FOR THE TREATMENT OF OPIOID ADDICTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2006-03-16 | — | — | WO | claimed |
| EP-1632227-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction | Laboratorios del Dr. Esteve S.A. (ES) | 2006-03-08 | — | — | EP | claimed |
| WO-2006010627-A1 | ARYL (OR HETEROARYL) AZOLYLCARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | claimed |
| WO-2005011684-A1 | MEDICAMENTS CONTAINING DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS | Grünenthal GmbH (DE) | 2005-02-10 | — | — | WO | claimed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| EP-1632227-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction | Laboratorios del Dr. Esteve S.A. (ES) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006010627-A1 | ARYL (OR HETEROARYL) AZOLYLCARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005011684-A1 | MEDICAMENTS CONTAINING DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS | Grünenthal GmbH (DE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194860-A1 | Pharmaceutical compositions containing aryl or heteroaryl azolylcarbinol compounds | CNR2, CNR1, CYP1B1 | SIGMAR1 517/4885HTT 597/4885SCN1A 590/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | SIGMAR1 162/4885HTT 1705/4885SCN1A 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.